As the pandemic has upended the FDA, the agency has been tested like never before. Now that the influx of new EUA requests has tapered slightly, the FDA has a chance to look back on how it managed to keep pace and decide what parts of its pandemic-era processes are worth keeping.

Endpoints News editor Zachary Brennan will explore these questions with a key FDA official. And then he’ll moderate a panel of top biopharma analysts and drugmakers to talk about the new regulatory landscape.

Click here for additional information and registration details.

Related Content

Evidence Matters 2022

Evidence Matters 2022

Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.